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Abstract
Purpose: The integrin avb3 is differentially expressed on neovascular endothelial cells. We investigated whether a novel
intravenously injectable avb3 integrin-ligand coupled nanoparticle (NP) can target choroidal neovascular membranes (CNV)
for imaging and targeted gene therapy.
Methods: CNV lesions were induced in rats using laser photocoagulation. The utility of NP for in vivo imaging and gene
delivery was evaluated by coupling the NP with a green fluorescing protein plasmid (NP-GFPg). Rhodamine labeling (Rd-NP)
was used to localize NP in choroidal flatmounts. Rd-NP-GFPg particles were injected intravenously on weeks 1, 2, or 3. In the
treatment arm, rats received NP containing a dominant negative Raf mutant gene (NP-ATPm-Raf) on days 1, 3, and 5. The
change in CNV size and leakage, and TUNEL positive cells were quantified.
Results: GFP plasmid expression was seen in vivo up to 3 days after injection of Rd-NP-GFPg. Choroidal flatmounts
confirmed the localization of the NP and the expression of GFP plasmid in the CNV. Treating the CNV with NP-ATPm-Raf
decreased the CNV size by 42% (P,0.001). OCT analysis revealed that the reduction of CNV size started on day 5 and
reached statistical significance by day 7. Fluorescein angiography grading showed significantly less leakage in the treated
CNV (P,0.001). There were significantly more apoptotic (TUNEL-positive) nuclei in the treated CNV.
Conclusion: Systemic administration of avb3 targeted NP can be used to label the abnormal blood vessels of CNV for
imaging. Targeted gene delivery with NP-ATPm-Raf leads to a reduction in size and leakage of the CNV by induction of
apoptosis in the CNV.
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Introduction
Age-related macular degeneration (AMD) is the leading cause of
blindness in developed countries for people over the age of 50
[1–3]. The neovascular or ‘‘wet’’ form of the disease, characterized
by the development of choroidal neovascular membranes (CNV) is
the main cause of visual impairment in macular degeneration
[3–5]. With the advent of new treatment options such as
photodynamic therapy, and especially intravitreal antiangiogenic
pharmacotherapy, the visual prognosis of patients with CNV has
improved significantly [6–9]. However, the current standard-of-
care therapies require monthly intravitreal injections by a retina
specialist due to their short half-life in the vitreous [10,11]. Aside
from the logistic difficulties and the patients’ discomfort, it also
puts the patient at risk for cataract formation, endophthalmitis,
vitreous hemorrhage, and retinal detachment. Thus, there is a
great need for alternative means of delivering antineovascular
therapy to the retina.
Recently, there has been substantial progress in the develop-
ment of nanoparticles with an integrin-targeted delivery system
[12–15]. During vascular remodeling and angiogenesis, several
integrins are expressed on the endothelial cells to potentiate cell
invasion and proliferation [16,17]. Among them, integrin avb3i s
expressed on many cell types but its expression level in normal
tissue is generally low [18,19]. It is preferentially expressed on
angiogenic blood vessels, mediating survival signal and facilitating
vascular cell proliferation [20,21]. Previous reports show that
integrin avb3 is involved in ocular angiogenesis [22,23]. In vivo
experiments have shown antibodies blocking or immunoconjugate
drug therapy targeting integrin avb3 inhibit neovascularizaion
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18864[17,23–26]. In addition, integrin avb3 potentiates the internaliza-
tion of various viruses [27,28], making it a potential target for drug
delivery via liposome based nanoparticles.
Previously we have shown that systemic injection of a cationic
nanoparticle coupled to an integrin avb3-targeting ligand (NP) can
deliver a suicide gene to the tumor neovasculature in rats, causing
apoptosis and significant tumor regression [12]. Here we evaluated
and were able to demonstrate that NP can target choroidal
neovascular membranes (CNV) in rats for imaging and targeted
gene therapy using a plasmid DNA encoding ATPm-Raf, a
dominant-negative mutant form of Raf kinase [29].
Materials and Methods
Animals and Ethics Statement
All experiments were conducted in accordance with the recom-
mendations in the Guide for the Care and Use of Laboratory Animals
of the National Institutes of Health.and the guidelines established by
the Animal Care Committee (ACC) of the Massachusetts Eye and Ear
Infirmary. The protocol was approved by the ACC (protocol number
07-10-012). A total of 106 Brown-Norway male rats weighing 175–
225 grams were obtained from Charles River Laboratories
(Wilmington, MA) and used for the experiments.
Characteristics and preparation of Nanoparticles
Detailed description of the NPs and their synthesis has been
published previously [12]. All custom-made lipids and genes were
GLP manufactured. Briefly, purified lipid components were
dissolved in organic solvents (CHCl3 and CH3OH in a ratio 1:1).
The CHCl3 and CH3OH were evaporated and dried in rotavap for
24 hours. Distilled and deionized water was added to yield a
heterogeneous solution of 30 mM in total lipid concentration. The
lipid/water mixture was then sonicated with a probe-tip sonicator
for at least one hour. Throughout sonication, the pH of the solution
was maintained between 7.0 and 7.5 with 0.01N NaOH solution,
and the temperature was maintained above the gel-liquid crystal
phase transition point (Tm). The liposome solution was transferred
to a petri dish resting on a bed of wet ice, cooled to 0uC, and
irradiated at 254 nm for at least one hour with a hand-held UV
lamp placed 1 cm above the petri dish, yielding NPs. The NPs were
then filtered through a 0.2 mm filter and collected.
Using a Brookhaven dynamic light scattering system (DLS), the
size (diameter), distribution, and zeta potential of NPs were
determined to be 45.3
+2.4 nm and +35mv respectively, averaged
for 17 cycles of NP synthesis.
The rats received intravenous treatments at a dose 1 mg/kg of
NP and 1 mg/kg of plasmid DNA containing the Raf mutant gene
(ATPm-Raf). Total volume of injection was 350 ml.
Induction of Choroidal Neovascular Membranes
Animals were anesthetized with an intraperitoneal injection of
0.2 to 0.3 mL of a 1:1 mixture of 100 mg/mL ketamine and
20 mg/mL xylazine. Pupils were dilated with 5.0% phenylephrine
and 0.8% tropicamide. CNV was induced in the eyes of rats with a
532-nm laser (Oculight GLx; Iridex, Mountain View, CA), as
previously described [30–32]. Four to eight laser spots (180 mW,
100 mm, 100 ms) were placed in each eye of the rat with a slit
lamp delivery system and a cover slip serving as a contact lens. If
significant hemorrhage occurred, the eye was excluded.
Evaluation of Specific Targeting of CNV Using In Vivo
Imaging and Choroidal Flatmounts
NP carrying a green fluorescing protein (GFP) plasmid (NP-
GFPg) was used to evaluate the ability of the particles to deliver a
gene to the neovascular endothelial cells. Rhodamine labeling of
the NP (Rd-NP) was used to localize the particles in choroidal
flatmounts. Rats were divided into 3 groups of 6 animals and
evaluated 1, 2, or 3 weeks after creation of CNV. The formation of
Figure 1. Bioimaging with NP-angiography showing GFP expression using the Topcon camera with fluorescein angiography filter
settings. Late phase FAs (A and D) show the CNV lesions prior to injection of NP. Autofluorescent images taken prior to injection of NP reveal
minimal background fluorescence of the CNV lesions (B and E). Injection of targeted NP carrying a GFP plasmid (NP-GFPg) causes increased
fluorescence of the CNV lesions from GFP expression (C) whereas non-targeted NP carrying a GFP plasmid (ntNP-GFPg) does not cause any increase in
the intensity of fluorescence of the CNV over background autofluorescence (F).
doi:10.1371/journal.pone.0018864.g001
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digital fundus camera (TCR50IA; Topcon, Paramus, NJ)
following intraperitoneal injection of 0.2 mL of 2% fluorescein
sodium. The rats where then injected with Rd-NP-GFPg particles.
The expression of GFP was evaluated with in vivo imaging using
the same camera and FA filter settings 24, 48, and 72 hours after
injection of particles. The rats were then euthanized and choroidal
flat mounts were performed at the above time points. RPE-
choroid-sclera complex was flatmounted (Vector Laboratories,
Burlingame, CA) and coverslipped. Pictures of the choroidal
flatmounts were taken by a confocal microscope (Leica Micro-
systems, Wetzler, Germany). Negative controls were evaluated
under identical conditions without injection of NP or following
injection of non-targeted rhodamine labeled liposome particles
carrying GFP-plasmid.
Treatment of CNV with Targeted Gene Delivery
After creation of laser-induced CNV, animals were divided in to
7 groups; groups A–C were treatment groups and groups D–G
were controls. Group A (n=6 received one intravenous injection
of anb3 targeted-NP containing ATPm-Raf (NP-ATPm-Raf) on
days 1, 3, and 5 after CNV creation; group B (n=6) received one
intravenous injection of NP-ATPm-Raf on days 3, 5, and 7; group
C (n=3) received one intravenous injection of NP-ATPm-Raf on
days 7, 9, and 11; group D (n=6) did not receive any treatment;
group E (n=3) received one intravenous injection of non-targeted
NP containing ATPm-Raf (ntNP-ATPm-Raf) on days 1, 3, and 5;
group F (n=3) received one intravenous injection of anb3
targeted-NP without ATPm-Raf (NP) on days 1,3, and 5; and
group G (n=3) received one intravenous injection of ATPm-Raf
gene without NP on days 1, 3, and 5.
Evaluation of CNV Size and Leakage
We used FA and OCT to monitor CNV development and
changes in vivo and choroidal flatmounts to study the size of the
lesions ex vivo. FA was performed as detailed above, 1 and 2 weeks
after CNV creation in all treated and control animals. A choroidal
neovascular membrane was defined as fully regressed after
treatment if there was no leakage in the area of treated membrane
[30,31]. The angiograms were graded by two masked readers
using a pre-established grading scheme [33,34]. Briefly, the
description of each grade follows: 0, faint hyperfluorescence or
mottled fluorescence without leakage; 1, hyperfluorescent lesion
without progressive increase in size or intensity; 2A, hyperfluor-
escence increasing in intensity but not in size; 2B, hyperfluores-
cence increasing in intensity and in size.
Two weeks after CNV creation, the size of the CNV lesions was
measured in choroidal flatmounts using the methods reported
previously after perfusion of 5 mg/mL fluorescein labeled dextran
[31,35]. A computer program (OpenLab; Improvision, Boston,
MA) was used by two masked investigators to measure the
hyperfluorescent areas corresponding to the CNV lesions.
Optical Coherence Tomography Measurement of CNV
Size
Six rats treated with intravenous NP-ATPm-Raf on days 1,3 and
5 and 6 control rats without treatment were used for evaluation of
CNV size in vivo using optical coherence tomography (SDOCT,
Bioptigen, Durham, NC) on days 3, 5, and 7 after CNV creation.
A volume analysis was performed, using 100 horizontal raster,
consecutive B-scan lines, each one composed of 1200 A-scans. The
volume size was 2.162.1 cm. To evaluate the cross-sectional size
of each lesion in OCT images, the sections passing through the
center of the CNV were chosen. The center of the lesion was
defined as the midline passing through the area of RPE-Bruch’s
membrane rupture. In order to consistently identify this point, we
used the en-face fundus reconstruction tool provided with the
Bioptigen SD-OCT system. For each time point, the same spot
was used to evaluate the size of the CNV. CNV was outlined from
the inner border of the retinal pigment epithelial layer to the top of
the lesion and the size was measured using Image J software
(http://rsbweb.nih.gov/ij/, last access January 7
th 2009).
Histopathology of CNV Lesions
On day 3,5, 7 and 14 after CNV creation, eyes were enucleated
and fixed in 4% paraformaldehyde in phosphate-buffered saline
Figure 2. Choroidal flatmounts showing accumulation of
rhodamine labeled NP and expression of GFP plasmid in the
CNV. The CNV lesions are delineated by arrowheads in bright field
images with false blue color (A and E). FITC-filtered images highlight the
GFP expression one day after systemic injection of Rd-NP-GFPg (B)
whereas non-targeted NP (Rd-ntNP-GFPg) does not induce GFP
expression in CNV (F). Cy3-filtered images highlight that rhodamine-
labeled NP (Rd-NP-GFPg) accumulates in the CNV (C), while rhodamine-
labeled non-targeted NP (Rd-ntNP-GFPg) does not (G). Some particles
can be visualized circulating in the choroidal vessels. Overlay of images
A–C is presented in panel D and overlay of E–G is shown in H.
doi:10.1371/journal.pone.0018864.g002
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were cut at 10 mm thickness on a cryostat (CM1850; Leica,
Heidelberger, Nussloch, Germany) at 220 C, and prepared for
staining. Terminal dUTP Nick-End Labeling (TUNEL) assay was
performed according to the manufacturer’s protocol (ApoTag
Fluorescein in situ Apoptosis Detection Kit; Chemicon, Temecula,
CA) as previously reported [31,36]. CD31 (1:100, Serotec,
Oxford, UK) antibody was used for visualizing endothelial cells
and a mouse monoclonal antibody for ED1, the rat homologue of
human CD68 (1:100, Millipore, Billerica, MA) was used for
staining macrophages. Sections were then stained with DAPI
(1:1000, Invitrogen Ltd, Carlsbad, CA, USA) for nuclear staining
and mounted with Vecta shield mounting media (Vector
Laboratories, Burlingame, CA). Photographs of the CNV were
taken with upright fluorescent microscope (DM RXA; Leica,
Solms, Germany) and the number of TUNEL positive and ED 1
positive cells were counted.
Statistical Analysis
All values are presented as mean 6 SE. Paired groups were
compared using the Wilcoxon t-test. For three groups, data were
compared by Kruskal-Wallis test and for two group comparisons,
Figure 3. Late phase fluorescein angiography (FA) and choroidal flatmounts (x10) two weeks after laser photocoagulation.
Representative lesions are from the control group (A–D) and the NP-ATPm-Raf treated group (E and F). Group (A) received no treatment; (B) received
intravenous injection of non-targeted NP containing ATPm-Raf on days 1, 3, and 5 after laser CNV creation; (C) received intravenous injection of anb3
targeted-NP without ATPm-Raf gene on days 1,3, and 5; (D) received injection of ATPm-Raf gene without NP on days 1, 3, and 5; (E) received injection
of anb3 targeted-NP containing ATPm-Raf (NP-ATPm-Raf) on days 1, 3, and 5; and (F) received injection of NP-ATPm-Raf on days 3, 5, and 7. NP-ATPm-Raf
treated groups (E and F) had significantly lower grade CNV lesions on FA grading and smaller CNV size compared to the control group (A–D). No
statistically significant difference in size was noted between the control groups A–D. Quantification of the CNV size on choroidal flat mounts is shown
in (G). *P,0.01. Data are expressed as the mean 6 SE.
doi:10.1371/journal.pone.0018864.g003
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Chicago, IL, USA). A P value of less than 0.05 was considered
statistically significant.
Results
In Vivo imaging Reveals GFP-Plasmid Expression by CNV
Formation of CNV was confirmed by FA prior to injection of
NP. One day after injection of rhodamine-labeled avb3 targeted
nanoparticle carrying a GFP plasmid (Rd-NP-GFPg), digital
fundus photography with FA filter settings revealed hyperfluores-
cence of the CNV lesions, confirming localization and adhesion of
the NP and GFP expression. This hyperfluorescence was sustained
through day 3 (data not shown) and was seen in 1, 2, and 3-week-
old CNV lesions examined (Figure 1A–C). There was no notable
hyperfluorescence noted above background fluorescence level in
the control groups (Figure 1D–F). There was no evidence of
increased fluorescence in the normal retinal or choroidal
vasculature.
Rhodamine-Labeled avb3 Targeted Nanoparticle
Accumulate in the CNV and Induce GFP Expression
The delivery of rhodamine dye and the expression of GFP
plasmid in the CNV were confirmed by performing confocal
microscopy on choroidal flat mounts (Figure 2). Choroidal
flatmounts performed after in vivo imaging revealed accumulation
of rhodamine labeled nanoparticles in the CNV lesion (Figure 2C).
There was an overlap of GFP expression and the rhodamine
accumulation in the CNV (Figure 2D). No notable difference was
seen in the pattern of NP accumulation or intensity of GFP
expression over the time course examined. There was no evidence
of increased fluorescence in the normal choroidal vasculature and
no evidence of rhodamine accumulation or GFP expression in the
control animal injected with non-targeted rhodamine labeled
nanoparticles carrying a GFP plasmid (Rd-ntNP-GFPg;
Figure 2E–H).
anb3 Targeted-NP Containing ATPm-Raf Reduces the Size
of CNV
Treatment of CNV with intravenous injection of anb3 targeted-
NP containing ATPm-Raf (NP-ATPm-Raf) on days 1, 3, and 5
resulted in a 42.0% reduction in the CNV size on choroidal
flatmount compared with control CNVs with no treatment (mean
size, 53538.7 mm
2 vs. 31029.3 mm
2,p ,0.001) (Figure 3A and E).
Treatment with 3 doses of NP-ATPm-Raf on days 3, 5 and 7 also
showed a 24.6% decrease in the CNV size (Figure 3F). Treatment
on days 7, 9, and 11 did not lead to a significant reduction of CNV
size (data not shown). Three additional control groups (n=3 each)
were given intravenous injection of non-targeted-NP containing
ATPm-Raf (ntNP- ATPm-Raf), naked ATPm-Raf, and anb3
targeted-NP with no ATPm-Raf (NP) on days 1,3, and 5 after
CNV formation. There was no difference in the CNV size
between any of the 4 control groups, including the no treatment
group (Kruskal- Wallis test, p=0.168) (Figure 3A–D).
To track the reduction of CNV size in vivo after treatment with
NP-ATPm-Raf, we used OCT imaging. We were able to delineate
the CNV as a discrete subretinal hyperreflective material starting
on day 5 (Figure 4B and C). While the difference in the cross-
sectional CNV size on day 5 between treated and control CNV
had not reached statistical significance, (Mann- Whitney U test,
p=0.066), significantly decreased size was noted on day 7 in the
treated group compared to the control group (Mann- Whitney U
test, p=0.001) (Figure 4A).
Treatment with NP-ATPm-Raf Leads to a Reduction in Size
and Leakage of CNV on FA
Quantitative assessment of CNV leakage by FA performed on
day 14 was carried out by two masked graders. Pathologic leakage
from the CNV could be noted in the late phase (6–8 minutes) in
the untreated group with large and diffuse area of leakage
(Figure 3A–D). The treated group showed less leakage with
smaller lesions (Figure 3E and F). FA grading revealed that
70%,83.8% of the CNV in the different control groups showed
grade 2B leakage, while 40.3% of the CNV in the treated group
had grade 2B leakage (Table 1; Pearson Chi- square test,
p,0.001). There was no difference in the distribution of grading
amongst the 4 different control groups (Pearson Chi- square test,
p=0.679). Also, no statistically significant difference was found in
the distribution of leakage grading between the groups treated on
days 1, 3, and 5 or days 3, 5, and 7 (Pearson Chi- square test,
p=0.152).
Reduced Endothelial Cell Count and Increased Apoptosis
in CNV Treated with NP-ATPm-Raf
CD31-positive endothelial cells were detected in the subretinal
space starting on day 3 after laser injury (figure 5D). The cells
increased and focalized to a distinct subretinal membrane
representing the CNV by day 7. In the treated CNV, there were
Figure 4. In vivo evaluation of CNV utilizing SD-OCT. Quantification of CNV size using SD-OCT (A) reveals a decrease in CNV size, reaching
statistical significance on day 7 (Mann- Whitney U test, p=0.001) in the NP-ATPm-Raf treated group compared to the control group. A hyper-reflective
subretinal lesion is seen as delineated by the red dotted line (B). This lesion corresponds to the hyporeflective area on fundus reconstruction (red
dotted circle, C). *P,0.01. Data are expressed as the mean 6 SE.
doi:10.1371/journal.pone.0018864.g004
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with distinct borders and fibrous formation by day 7 (Figure 5D).
We investigated signs of apoptosis with TUNEL staining. In the
treated group, significantly more TUNEL-positive nuclei were
observed in the CNV starting on day 3 (Figure 5A and B). This
trend continued through day 7 (Mann Whitney U test, p,0.01 for
day 3 and 5, p=0.01 for day 7, Figure 6B). The reduction of the
CNV size as measured in histological sections reached statistical
significance on day 7 (Mann Whitney U test, P=0.001, Figure 6C).
Macrophage infiltration with anb3 Targeted-NP
Containing ATPm-Raf
ED 1 positive cells (a marker for macrophages, equivalent to
human CD 68) were concentrated within the subretinal space at
the laser injury site on day 3 (Figure 6D). No ED 1-positive cells
were observed in the undamaged choroid. No difference was
noted in the number of ED 1-positive cells infiltrated into the
CNV between the treated group and the untreated group on day
3. However, on day 5 and 7 statistically more ED 1-positive cells
were seen in the treatment group (Mann Whitney U test, P,0.01
respectively; Figure 6D).
Discussion
Specific targeting and delivery of medication for the treatment
of CNV remains challenging [37]. In this study we were able to
target experimental CNV after systemic injection of a cationic
Table 1. Fluorescein angiography (FA) grading of CNV
lesions.
Grade 1 Grade 2A Grade 2B Total
Control 5(6.2%) 16(19.8%) 60(74.1%) 81
ntNP-ATPm-Raf 2(5%) 10(25%) 28(70%) 40
ATPm-Raf 3(7.1%) 7(16.7%) 32(76.2%) 42
NP 0(0%) 6(16.2%) 31(83.8%) 37
NP-ATPm-Raf on D1, 3, 5 10(13.9%) 33(45.8%) 59(40.3%) 72
NP-ATPm-Raf on D3, 5, 7 1(2.8%) 16(44.4%) 19(52.8%) 36
Significantly higher percentage of control CNV lesions were Grade 2B compared
to the treated CNV (Pearson Chi-square test P,0.001). There were no significant
differences between the different treatment groups (Pearson Chi-square test
P=0.679).
doi:10.1371/journal.pone.0018864.t001
Figure 5. Evaluation of endothelial cell apoptosis with TUNEL staining in frozen sections. Quantification of TUNEL positive cells showed
significantly more TUNEL(+) cells/lesion (A) and TUNEL (+) cells/mm
2 (B) with treatment of NP-ATPm-Raf compared to the control group on day 3 and
5 after laser injury. There was a statistically significant reduction of CNV size noted on day 7(C). Double-immunofluorescent staining of frozen sections
(x20) obtained at 3, 5 and 7 days after laser photocoagulation for the endothelial cell marker CD31 and TUNEL stain (D). *P,0.01. Data are expressed
as the mean 6 SE.
doi:10.1371/journal.pone.0018864.g005
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and utilize this method for imaging and treatment of CNV in rats.
We first demonstrated the vascular targeting of NP and it’s
ability to deliver a gene to the neovascular endothelial cells of
CNV in rats using rhodamine labeled NPs coupled with GFP (Rd-
NP-GFPg). GFP expression was seen in vivo using fundus NP-
angiography with FA filter settings and ex vivo in choroidal flat
mounts. In vivo imaging revealed increased fluorescence, sustained
for 3 days after NP injection, in 1, 2, or 3 week old CNV (figure 1).
GFP expression co-localized to the area of rhodamine labeled NP
accumulation in the CNV on choroidal flat mounts indicating
GFP expression is correlated with areas of NP adhesion to
neovascular endothelial cells of CNV (figure 2). None of the retinal
or choroidal vasculature showed increased fluorescence from GFP
expression. The specific targeting of NP is due to the selectivity of
its binding ligand for integrin avb3 [12], which has limited cellular
distribution in normal tissue including the eye [23,38]. This
integrin is significantly up regulated during the process of vascular
remodeling and angiogenesis and is present in pathologic
specimens from human eyes with CNV or proliferative diabetic
retinopathy (PDR) [17,22,23,39,40]. With the specific labeling of
CNV demonstrated here, fundus NP-angiography utilizing various
dyes has the potential to be a novel imaging technique for
detecting new CNV or to follow CNV activity independent of
CNV size and leakage. Recently, Takeda and colleagues have
shown early detection of experimental CNV, not visible on FA,
using a similar technique with anti-CCR3 antibody fragments
[41]. The advantage of using NPs over immunoconjugate dyes in
bioimaging and targeted therapy is that they are less likely to incite
an immune reaction.
In the treatment arm of the study, we were able to demonstrate
significant reduction of CNV size and leakage by targeted gene
therapy using NP coupled to ATPm-Raf, a dominant negative
form of Raf kinase (Figure 3, 4). Previously Singh et al treated
experimental CNV using poly-lactide-co-glycolide (PLGA) nano-
particles carrying a VEGF inhibitory gene [42]. Our approach is
different in a number of ways including the type of particles used,
specificity of targeting, and the gene delivered. The particles that
Singh et al used had a negative z-potential as expected for PLGA
nanoparticles, our therapy has a neutral charge and therefore is
not toxic in tissue-cultured cells. Our nanoparticles are smaller
(45.3 nm vs. 270–420 nm) and form a stable shell through
covalent bonds that are far more stable in blood circulation than
polymer based (used by Sing et al and hydrolyzed in aqueous
Figure 6. Increased macrophage infiltration at the site of treated CNV. Macrophage infiltration was highest on day 3 with gradual decrease
on days 5 and 7. Significantly higher number of macrophages were observed with the NP-ATPm-Raf treated group compared to the control group on
days 5 and 7 (A and B). There was a statistically significant reduction of CNV size noted on day 7(C). Immunofluorescent staining of representative
frozen sections (x20) obtained at 3, 5, and 7 days after laser photocoagulation for ED 1, a marker for macrophage (D). *P,0.01. Data are expressed as
the mean 6 SE.
doi:10.1371/journal.pone.0018864.g006
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may lead to more efficacy and/or more side effects. A separate
toxicity study is planned to answer this question. The targeted
gene, Raf kinase, is an integral member of an intracellular signal
transduction pathway involved in regulation of the cell cycle.
ATPm-Raf is a mutant form of Raf-l that fails to bind ATP and
blocks the endothelial cell Raf activity in vitro [12,29]. Raf-1
mutation has been linked to vascular defect and apoptosis during
embryogenesis and gene therapy with ATPm-Raf causes endothe-
lial cell apoptosis and tumor regression in rats [12,43]. Our results
indicate a similar mechanism of CNV regression, through
induction of apoptosis in neovascular endothelial cells, after
targeted gene therapy with NP-ATPm-Raf. There were signifi-
cantly higher number of TUNEL positive cells in the treated CNV
as compared to the controls (Figure 5). Moreover, while the
recruitment of macrophages per lesion decreased with time in both
groups, more macrophage infiltration was noted on days 5 and 7
in the treatment group (Figure 6). The initial spike in macrophage
infiltration is likely the result of the inflammatory response to the
laser injury. The increased macrophage recruitment to the treated
CNV closely follows the increased apoptotic activity, suggesting
that the macrophages may be responding to cell death by
apoptosis or necroptosis.
Repeated systemic administration of NP for the treatment of
CNV may lead to side effects such as blood clots in the elderly
patient population. However, Intravenous (I.V.) administration of
our treatment is not repetitious as apposed to the intravitreal
injections of anti-VEGF therapies for example. In addition, for
some patients, I.V. injections are less invasive than intravitreal
injections and do not carry the potential ocular complications.
Furthermore, due to the specificity of the binding site, the dose of
nanoparticles needed is small and the tissue distribution limited,
making systemic side effects less likely. In our study, we did not
attempt the intreavitreal route of delivery as part of the
investigation. Due to the large size of the NP (45.3 nm), it is
unclear if it can distribute through the vitreous and cross the retina
to reach the lumen of the CNV vessels through phagocytosis,
pinocytosis or other mechanisms.
We also explored the timing of imaging and treatment with
targeted NP in our study. Although we were able to target CNV
with NP and capture GFP expression by NP-angiography up to
three weeks after CNV induction, the maximum efficacy of
treatment was achieved when treatment was given on days 1,3 and
5 (42% reduction in CNV size). We saw a modest decrease in the
CNV size (24.6%) when the treatment was given on days 3, 5 and
7 and found no effect with treatment on days 7, 9 and 11. This
data is consistent with the timing of integrin avb3 expression in the
laser induced CNV in rats [44]. Integrin avb3 is expressed up to 4
weeks after laser injury, however its expression levels are
significantly higher in the early stages of CNV formation, peaking
at day 7 [44]. The fact that we were unable to show CNV
regression with treatment starting at later time points may be due
to the concentrations of NP used or the efficacy of transfecting the
CNV endothelial cells with ATPm-Raf. Integrin avb3 expression
has been shown in pathologic specimens from human CNV and
diabetic retinopathy [23,45], however, the timing and duration of
expression of this integrin has not been studied.
In summary, our results provide evidence that systemic
administration of avb3 targeted NP can be used to label the
abnormal blood vessels of CNV for imaging and targeted gene
therapy with ATPm-Raf. These results provide a proof-of-concept
for this emerging technology and encourage further experimen-
tation to discern the integration of NPs into current imaging and
treatment of CNV and retinal neovascularization. Large animal
studies and experiments utilizing NP coupled to various dyes and
chemotherapeutic or anti-neovascular compounds need to be
pursued to further explore the efficacy of this diagnostic and
treatment strategy.
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